*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].
asthma
Phase 3
No
-
All
695
Interventional
18 Years - 70 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2016 by Takeda
Takeda
-
No locations available
Arms | Assigned Interventions |
---|